je.st
news
Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
2015-04-28 00:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that The Lancet and Clinical Infectious Diseases have published online the results from the pivotal Phase 3 clinical studies of ZERBAXA (ceftolozane/tazobactam) for Injection (1 g/0.5 g) in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), respectively. The results will also appear in forthcoming print issues of the journals. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558Robert Consalvo, 908-295-0928orInvestor Contacts:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
publication
studies
Category:Biotechnology and Pharmaceuticals